The Hospital Association of South Africa (HASA) has announced its new Board of Directors. They were elected at HASA’s Annual General Meeting on 2nd October 2018.
The HASA Board of Directors Chairman is Dr Biren Valodia, the Chief Marketing Officer for Mediclinic South Africa; and the HASA Deputy Chairman is Matthew Prior, the Life Healthcare Funder Relations and Health Policy Executive.
Other members of the HASA Board of Directors include Melanie Da Costa, the Netcare Director of Strategy and Health Policy; Amil Devchand, the Chairman of the National Hospital Network; Lynelle Bagwandeen, the Netcare Company Secretary and General Counsel; Dr Paul Soko, the Life Healthcare Executive Head of Clinical Services and Quality; Clara Findlay, Mediclinic South Africa Head of Legal Services; and Elsabe Conradie, the CEO of the National Hospital Association.
CEO Dr Dumisani Bomela is the executive representative on the Board and is unaligned to any of the HASA member groups. Tienie van den Berg, the CEO of Zuid-Afrikaans Hospital, has retired from the Board but has agreed to continue to serve the organisation as Treasurer.
During the annual meeting, incoming Chairman Dr Valodia welcomed the election of the Board and paid tribute to the outgoing chairman, Melanie Da Costa.
“Melanie held the reins and directed the organisation through a period of legislative and regulatory complexity, until the tabling of National Health Insurance (NHI) and the Medical Schemes Amendment Bills and the release of the Healthcare Market Inquiry provisional report and recommendations. Her deep and insightful knowledge of policy and her far-sightedness in healthcare system issues enabled us to make a number of positive contributions to the many debates underway, and in so doing crucially helped HASA to represent the private hospital system in engagements with key stakeholders,” said Dr Valodia.
“She has given the organisation strong leadership and purpose during her tenure and we are all grateful to her for her massive contribution to the organisation, the private hospital sector, and to healthcare reform. Fortunately, Melanie remains on the Board and in typically selfless fashion, she will help the Board through this transition and will continue to make an invaluable contribution in these still-complex health reform processes,” conclude Dr Valodia.